Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 120Lymphoma 90Lymphoma, Large B-Cell, Diffuse 79Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Burkitt Lymphoma 31Multiple Myeloma 26Lymphoma, Non-Hodgkin 26Lymphoma, Follicular 26Leukemia 26Hodgkin Disease 24Lymphoma, Mantle-Cell 18Neoplasms 16Lymphoma, T-Cell, Peripheral 16Lymphoma, B-Cell 14Lymphoma, Large-Cell, Immunoblastic 12Lymphoma, Large-Cell, Anaplastic 11Dendritic Cell Sarcoma, Interdigitating 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Recurrence 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Lymphocytic, Chronic, B-Cell 8Neoplasms, Plasma Cell 7Neoplasm Metastasis 7Waldenstrom Macroglobulinemia 6Primary Myelofibrosis 6Lymphoma, T-Cell 6Immunoblastic Lymphadenopathy 6HIV Infections 5Graft vs Host Disease 5Blast Crisis 5

Interventions

Prednisone 1Dexamethasone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hyperaldosteronism × Prednisone × Clear all
NCT01867710 2019-07-05

Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy

Janssen Pharmaceutica N.V., Belgium

Phase 2 Completed
164 enrolled 22 charts
Genitourinary

Hyperaldosteronism, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡